Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome
Author(s) -
Heping Zhang,
Richard S. Legro,
Jian Zhang,
L. Zhang,
Xiang Chen,
Hao Huang,
Peter R. Casson,
William D. Schlaff,
Michael P. Diamond,
Stephen A. Krawetz,
Christos Coutifaris,
Robert G. Brzyski,
Gregory M. Christman,
Nanette Santoro,
Esther Eisenberg
Publication year - 2010
Publication title -
human reproduction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.446
H-Index - 226
eISSN - 1460-2350
pISSN - 0268-1161
DOI - 10.1093/humrep/deq210
Subject(s) - polycystic ovary , randomized controlled trial , ovulation , clinical trial , medicine , gynecology , insulin resistance , hormone , insulin
Double-blind, randomized clinical trials are the preferred approach to demonstrating the effectiveness of one treatment against another. The comparison is, however, made on the average group effects. While patients and clinicians have always struggled to understand why patients respond differently to the same treatment, and while much hope has been held for the nascent field of predictive biomarkers (e.g. genetic markers), there is still much utility in exploring whether it is possible to estimate treatment efficacy based on demographic and baseline variables.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom